Private Financing News
Tragara Pharmaceuticals, Inc., Corporation just had published form D about $13.06 million equity financing. This is a new filing. Tragara Pharmaceuticals was able to fundraise $13.06 million. That is 100.00% of the financing round. The total fundraising amount was $13.06 million. The financing document was filed on 2015-09-01.
Tragara Pharmaceuticals is based in California. The filler’s business is Pharmaceuticals. The form D was submitted by Thomas M Estok President and Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 3152 Lionshead Avenue, Carlsbad, Ca, California, 92010. Thomas M. Estok is the related person in the form and it has address: C/O Tragara Pharmaceuticals, Inc., 3152 Lionshead Avenue, Carlsbad, Ca, California, 92010. Link to Tragara Pharmaceuticals Filing: 000114036115034154.
On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering size. Tragara Pharmaceuticals sold 100.00% of the offering. Could this mean that the trust in Tragara Pharmaceuticals is high? The average fundraising size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 2,248.70% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this financing was set at $0. If you know more about the reasons for the financing, please comment below.
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
The Form D signed by Thomas M Estok might help Tragara Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
19 September 2017
19 September 2017